Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial.
Julie DubourgPascale FouquerayDamien QuinslotJean-Marie GrouinKohei KakuPublished in: Diabetes, obesity & metabolism (2021)
Imeglimin provides well-tolerated long-term safety and efficacy in both mono- and oral combination therapy in Japanese patients with type 2 diabetes. This article is protected by copyright. All rights reserved.